James M. Cleary

19.2k total citations
157 papers, 3.8k citations indexed

About

James M. Cleary is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, James M. Cleary has authored 157 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 47 papers in Surgery. Recurrent topics in James M. Cleary's work include Colorectal Cancer Treatments and Studies (36 papers), Pancreatic and Hepatic Oncology Research (30 papers) and Gastric Cancer Management and Outcomes (29 papers). James M. Cleary is often cited by papers focused on Colorectal Cancer Treatments and Studies (36 papers), Pancreatic and Hepatic Oncology Research (30 papers) and Gastric Cancer Management and Outcomes (29 papers). James M. Cleary collaborates with scholars based in United States, Spain and Canada. James M. Cleary's co-authors include Geoffrey I. Shapiro, Andrew J. Aguirre, Alan D. D’Andrea, Andrew X. Zhu, Shuchi S. Pandya, Brian M. Wolpin, Nikhil H. Ramaiya, Charles S. Fuchs, Douglas A. Rubinson and Kimmie Ng and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Molecular Cell.

In The Last Decade

James M. Cleary

150 papers receiving 3.7k citations

Peers

Countries citing papers authored by James M. Cleary

Since Specialization

Citations

This map shows the geographic impact of James M. Cleary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Cleary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Cleary more than expected).

Fields of papers citing papers by James M. Cleary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Cleary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Cleary. The network helps show where James M. Cleary may publish in the future.

Co-authorship network of co-authors of James M. Cleary

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Cleary. A scholar is included among the top collaborators of James M. Cleary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Cleary. James M. Cleary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas 2025 ·The American Journal of Surgical Pathology ·(unknown), James M. Cleary, (unknown), Jason L. Hornick, Lei Zhao	0
2	Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649. 2025 ·Journal of Clinical Oncology ·Yelena Y. Janjigian, Markus Moehler, Jaffer A. Ajani, (unknown), Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M. Cleary, (unknown), Ricardo Brugés, Michalis V. Karamouzis, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Mustapha Tehfé, Stephen McCraith, Nan Hu, Jennifer Zhang, Kohei Shitara	1
3	A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma. 2024 ·Journal of Clinical Oncology ·Robin Kate Kelley, James M. Cleary, Vaibhav Sahai, Marina Baretti, John Bridgewater, Zhaowei Hua, Camelia Gliser, Ying Bian, Ghassan K. Abou‐Alfa	1
4	A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors 2024 ·Clinical Cancer Research ·Gregory M. Coté, Bose Kochupurakkal, T. Khanh, Andrea J. Bullock, Michael L. Cheng, Alona Muzikansky, Daniel E. McLoughlin, James M. Cleary, (unknown), Aparna R. Parikh, Jong Chul Park, Colin D. Weekes, Oladapo Yeku, Lee Zou, Geoffrey I. Shapiro	4
5	Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649. 2024 ·Journal of Clinical Oncology ·(unknown), Kohei Shitara, Markus Moehler, Jaffer A. Ajani, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M. Cleary, (unknown), Michalis V. Karamouzis, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Mustapha Tehfé, Kynan Feeney, Rui Wang, Raheel Nathani, Yelena Y. Janjigian	3
6	1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Alison M. Schram, Kōichi Goto, Dongwook Kim, Antoine Hollebecque, Sun Young Rha, Kazumi Nishino, M. Duruisseaux, (unknown), Joon Oh Park, Natasha B. Leighl, Teresa Macarulla, Stephen V. Liu, Mohammed Najeeb Al Hallak, James M. Cleary, Cindy Neuzillet, Yasushi Goto, Andrew K. Joe, (unknown), (unknown), Alexander Drilon	10
7	664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors 2023 ·Annals of Oncology ·Ryan B. Corcoran, T. Khanh, James M. Cleary, Aparna R. Parikh, Oladapo Yeku, Colin D. Weekes, Leanne G. Ahronian, Gianluca Mauri, Ju Tian, Joan S. Brugge, Dejan Juric, K. T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, U. Matulonis, (unknown), Geoffrey I. Shapiro	1
8	SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach 2023 ·Modern Pathology ·Alexander J. Neil, Lei Zhao, Raymond A. Isidro, Amitabh Srivastava, James M. Cleary, Fei Dong	16
9	A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C 2023 ·Cancer Chemotherapy and Pharmacology ·Richard D. Kim, Alexis D. Leal, Aparna R. Parikh, David P. Ryan, Shining Wang, Brittany Bahamón, Neeraj Gupta, Aaron J. Moss, (unknown), Harry Miao, Haig Inguilizian, James M. Cleary	12
10	Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF‐mutant solid tumors 2023 ·Cancer ·Meghan J. Mooradian, James M. Cleary, Anita Giobbie‐Hurder, Lancia Darville, Aparna R. Parikh, Elizabeth I. Buchbinder, Justine V. Cohen, Donald P. Lawrence, Geoffrey I. Shapiro, Harold Keer, Helen X Chen, Susan Percy Ivy, Keiran S.M. Smalley, John M. Koomen, Ryan J. Sullivan	7
11	595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Dongwook Kim, Kōichi Goto, Alison M. Schram, Antoine Hollebecque, Sun Young Rha, Kazumi Nishino, M. Duruisseaux, (unknown), Joon Oh Park, Natasha B. Leighl, T. Macarulla Mercadé, Stephen V. Liu, Mohammed Najeeb Al Hallak, James M. Cleary, Cindy Neuzillet, Yasushi Goto, Andrew K. Joe, (unknown), (unknown), Alexander Drilon	1
12	Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy 2022 ·Journal of Gastrointestinal Cancer ·Renata D’Alpino Peixoto, (unknown), James M. Cleary, (unknown), (unknown), Alexandre A. Jácome	4
13	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial 2021 ·The Oncologist ·Aminah Jatoi, Fang‐Shu Ou, Daniel H. Ahn, Tyler Zemla, Jennifer Le‐Rademacher, Patrick M. Boland, Kristen K. Ciombor, Nisha L. Jacobs, Boris Pasche, James M. Cleary, Jeannine S. McCune, Katrina S. Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Erica N. Heying, Heinz‐Josef Lenz, Jeff A. Sloan, Axel Grothey, Mario E. Lacouture, Tanios Bekaii‐Saab	5
14	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations 2019 ·Clinical Cancer Research ·Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric‐Bernstam, Josep Tabernero, Filip Jankú, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, (unknown), Valerie Nicolas‐Métral, (unknown), Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, José Baselga	102
15	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma 2016 ·Clinical Cancer Research ·Kent W. Mouw, James M. Cleary, Brendan Reardon, (unknown), Lior Z. Braunstein, Jaegil Kim, Ali Amin‐Mansour, Diana Miao, (unknown), Joanna Chin, Patrick A. Ott, Charles S. Fuchs, Neil E. Martin, Gad Getz, Scott L. Carter, Harvey J. Mamon, Jason L. Hornick, Eliezer M. Van Allen, Alan D. D’Andrea	36
16	Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors 2015 ·Clinical Cancer Research ·John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Jeffrey W. Clark, John Kauh, Glen J. Weiss, James M. Cleary, Devalingam Mahalingam, Michael D. Pickard, Hélène M. Faessel, Allison Berger, Kristine Burke, George Mulligan, Bruce J. Dezube, R. Donald Harvey	139
17	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors 2015 ·Investigational New Drugs ·Suzanne F. Jones, Lillian L. Siu, Johanna C. Bendell, James M. Cleary, Albiruni R. Abdul Razak, Jeffrey R. Infante, Shuchi S. Pandya, Philippe L. Bédard, Kristen J. Pierce, Brett E. Houk, W. Gregory Roberts, S. Martin Shreeve, Geoffrey I. Shapiro	125
18	A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014 2014 ·Clinical Cancer Research ·Wells A. Messersmith, Geoffrey I. Shapiro, James M. Cleary, Antonio Jimeno, Arvind Dasari, Bo Huang, M. Naveed Shaik, Rossano Cesari, Xianxian Zheng, Jennifer M. Reynolds, Patricia A. English, Karen R. McLachlan, Kenneth A. Kern, Patricia LoRusso	175
19	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma 2014 ·The Oncologist ·Brian M. Wolpin, Douglas A. Rubinson, Xiaoxu Wang, Jennifer A. Chan, James M. Cleary, Peter C. Enzinger, Charles S. Fuchs, Nadine J. McCleary, Jeffrey A. Meyerhardt, Kimmie Ng, Deborah Schrag, (unknown), Beverly Spicer, (unknown), Harvey J. Mamon, Alec C. Kimmelman	289
20	Sunitinib rechallenge in metastatic renal cell carcinoma patients 2010 ·Cancer ·Ivan Zama, Thomas E. Hutson, Paul Elson, James M. Cleary, Toni K. Choueiri, Daniel Y.C. Heng, Nikhil H. Ramaiya, M. Dror Michaelson, Jorge A. García, Jennifer J. Knox, Bernard Escudier, Brian I. Rini	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact